Chris T. Williamson

Abstract Sun705: Comparison of 5-Year Neurologically Intact Survival Between an Automated Head Up CardiopulmonaryResuscitation Registry and a National Cardiac Arrest Registry

Johanna Moore, Kerry M. Bachista, Bayert J. Salverda, Jeff Wittmer et autres

Background: Pre-clinical animal studies have demonstrated improved cerebral blood flow and neurological survival with Automated Head Up Position (AHUP) cardiopulmonary resuscitation (CPR) as compared to flat conventional (C) CPR. AHUP CPR consists of 1) automated head and thorax elevation 2) active compression …

us, tt, fr (code pays fourni par la source)

Abstract 385: Comparison of Rapid Implementation of Automated Head and Thorax Elevation With Active Compression Decompression Cardiopulmonary Resuscitation and an Impedance Threshold Device versus National Outcome Data: A Prospective Observational Study

Johanna Moore, Kerry M. Bachista, R. P. Quinn, Lauren Emanuelson et autres

Background: Pre-clinical work has shown automated head and thorax elevation with active compression decompression CPR and an impedance threshold device (AHUP-CPR) improved 24-hour neurological survival. Propensity matched studies of out-of-hospital-cardiac arrest (OHCA) patients have shown a time dependent association between survival to …

us (code pays fourni par la source)

Supplementary Figures from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson et autres

Supplementary Figure 1 ARID1A mutations in the panel of OCCC tumour cell line models with corresponding protein expression. Supplementary Figure 2 Un-cropped western blots from main and supplementary figures. Supplementary Figure 3 ARID1A selective effects from the high throughput drug screen. Supplementary …

Supplementary Table 12 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson et autres

Results from the siRNA kinase and tumour suppressor dasatinib resistance screen, see also Figure 5

Supplementary Table 3 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson et autres

Additional compounds included in the isogenic high-throughput drug screen

Supplementary Table 11 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson et autres

Results from the dasatinib target siRNA screen, see also Figure S6

Supplementary Table 2 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson et autres

Compounds used in the high throughput drug screen in the panel of OCCC cell lines

Supplementary Figure legends and methods from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson et autres

Figure legends for Supplementary figures and supplementary methods

Supplementary Table 10 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson et autres

MS Stats output from dasatinib bead proteomics, see also Figure 3

Supplementary Table 1 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson et autres

Supplier and catalogue number of compounds included in high-throughput drug screen

Data from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson et autres

Abstract New targeted approaches to ovarian clear cell carcinomas (OCCC) are needed, given the limited treatment options in this disease and the poor response to standard chemotherapy. Using a series of high-throughput cell-based drug screens in OCCC tumor cell models, we have …

Supplementary Table 8 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson et autres

Pearson's correlation and Z prime values for isogenic cell lines demonstrating robust reproducibility and dynamic range from the high-throughput drug screen, see also Figure 1